TIL will hold a meeting of the Board of Directors of the Company on 5 March 2026.

Mangal Credit & Fincorp will hold a meeting of the Board of Directors of the Company on 5 March 2026.

Kabra Extrusion Technik has secured a contract manufacturing order worth Rs 133 crore for energy storage.

BCC Fuba India will hold a meeting of the Board of Directors of the Company on 5 March 2026.

Bharat Electronics announced that the Board of Directors of the Company at its meeting held on 27 February 2026, inter alia, have recommended the interim dividend of Rs 1.95 per equity Share (i.e. 195%) , subject to the approval of the shareholders.

Dredging Corporation of India announced that Lav Verma, IAS (Retd.), ceased to be an Independent Director of the Company with effect from 28 February 2026 upon completion of his tenure of three years.

SGL Resources will hold a meeting of the Board of Directors of the Company on 3 March 2026.

Caplin Steriles (Caplin), a Subsidiary Company of Caplin Point Laboratories, has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Desmopressin Acetate Injection USP, 4 mcg/mL single-dose vials and 40 mcg/10 mL (4 mcg/mL) multiple-dose vials, a generic therapeutic equivalent version of the Reference Listed Drug (RLD) DDAVP (desmopressin acetate) Injection, 4 mcg/mL of Nordic Pharma Inc., (NDA 018938).

Desmopressin Acetate Injection is used to treat conditions like haemophilia A, von Willebrand disease, and central diabetes insipidus, helping to manage bleeding and regulate urine production. According to IQVIATM (IMS Health), Desmopressin Acetate injection USP, 4 mcg/mL single-dose vials and 40 mcg/10 mL (4 mcg/mL) multiple-dose vials had US sales of approximately $26 million for the 12-month period ending December 2025.

Saboo Sodium Chloro will hold a meeting of the Board of Directors of the Company on 5 March 2026.

The Board of ICICI Bank at its meeting which concluded today i.e. 28 February 2026, approved purchase of up to 2.0% additional shareholding in its subsidiary, ICICI Prudential Life Insurance Company (ICICI Life). This purchase will primarily be towards maintaining the Bank's majority shareholding in the event of exercise of stock-based compensation of ICICI Life. The above will be subject to receipt of requisite approvals.